ArticleInfection and immunity2023
Class-Driven Synergy and Antagonism between a Pseudomonas Phage and Antibiotics.
Article in Infection and immunity, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- Systematic combinatorial optimization of three-phage cocktails against multidrug-resistantMicrobiology spectrum · 2026Article
- Dynamics of multidrug-resistant avian pathogenic E. coli biofilm formation on various surfaces and its dispersion with phage antibiotic synergism.BMC microbiology · 2026Article
- Discovery and characterization of a novelPHAGE (New Rochelle, N.Y.) · 2026Article
- Natural products influence bacteriophage infectivity.Natural product reports · 2025Review
- Phage-Antibiotic Combinations for Pseudomonas: Successes in the Clinic and In Vitro Tenuously Connected.Microbial biotechnology · 2025Review
- Unlocking Enhanced Efficacy of Aminoglycoside Antibiotics Against Pseudomonas aeruginosa.Microbial biotechnology · 2025Review
- The Current Landscape of Phage-Antibiotic Synergistic (PAS) Interactions.Antibiotics (Basel, Switzerland) · 2025Review
- One-Two Punch: Phage-Antibiotic Synergy Observed againstACS omega · 2025Article
- In Vitro Interactions Between Bacteriophages and Antibacterial Agents of Various Classes Against Multidrug-Resistant Metallo-β-Lactamase-ProducingPharmaceuticals (Basel, Switzerland) · 2025Article
- CombatingFrontiers in cellular and infection microbiology · 2025Review
- Phage-antibiotic combinations againstFrontiers in microbiology · 2025Article
- Exploring synergistic and antagonistic interactions in phage-antibiotic combinations against ESKAPE pathogens.Microbiology spectrum · 2024Article
- A Case of Persistent Intra-AbdominalPHAGE (New Rochelle, N.Y.) · 2024Article
- Bacteriophage Therapy on an In Vitro Wound Model and Synergistic Effects in Combination with Beta-Lactam Antibiotics.Antibiotics (Basel, Switzerland) · 2024Article
- Phage-induced efflux down-regulation boosts antibiotic efficacy.PLoS pathogens · 2024Article
- Synergistic removal ofFrontiers in microbiology · 2024Article
- The Respiratory Microbiome in Paediatric Chronic Wet Cough: What Is Known and Future Directions.Journal of clinical medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
The ubiquitous bacterial pathogen Pseudomonas aeruginosa is responsible for severe infections in patients with burns, cystic fibrosis, and neutropenia. Biofilm formation gives physical refuge and a protected microenvironment for sessile cells, rendering cure by antibiotics a challenge. Bacteriophages have evolved to prey on these biofilms over millions of years, using hydrolases and depolymerases to penetrate biofilms and reach cellular targets. Here, we assessed how a newly discovered KMV-like phage (ΦJB10) interacts with antibiotics to treat P. aeruginosa more effectively in both planktonic and biofilm forms. By testing representatives of four classes of antibiotics (cephalosporins, aminoglycosides, fluoroquinolones, and carbapenems), we demonstrated class-dependent interactions between ΦJB10 and antibiotics in both biofilm clearance and P. aeruginosa killing. Despite identifying antagonism between some antibiotic classes and ΦJB10 at early time points, all classes showed neutral to favorable interactions with the phage at later time points. In one notable example where the antibiotic alone had poor activity against both biofilm and high-density planktonic cells, we found that addition of ΦJB10 demonstrated synergy and resulted in effective treatment of both. Further, ΦJB10 seemed to act as an adjuvant to several antibiotics, reducing the concentration of antibiotics required to ablate the biofilm. This report shows that phages such as ΦJB10 may be valuable additions to the armamentarium against difficult-to-treat biofilm-based infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.